Israeli biotech MemoryPlus has developed a peptide to block the interaction of proteins PTEN & PSD-95, that causes memory loss in Alzheimer’s patients. The disease makes excessive PTEN, which attacks PSD-95, weakening the brain’s synapses. The peptide also lowers PTEN levels.
https://nocamels.com/2023/08/protein-busting-drug-could-be-new-era-for-alzheimers-therapy/